Koji Fukuda

ORCID

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 4

Top Venues

Cancer science

NPJ precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Naohiro Yanagimura, Shinji Takeuchi, Koji Fukuda, Sachiko Arai, Azusa Tanimoto, Akihiro Nishiyama, Naohisa Ogo, Hiroyuki Takahashi, Akira Asai, Satoshi Watanabe, Toshiaki Kikuchi, Seiji Yano
STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis. NPJ precision oncology 6 (1) (2022)
Chiaki Suzuki, Akihiro Nishiyama, Sachiko Arai, Shoichiro Tange, Atsushi Tajima, Azusa Tanimoto, Koji Fukuda, Yohei Takumi, Hiroshi Kotani, Shinji Takeuchi, Naohiro Yanagimura, Koushiro Ohtsubo, Norio Yamamoto, Koichi Omori, Seiji Yano
Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells. Cancer science 113 (7) (2022)
Koji Fukuda, Sakiko Otani, Shinji Takeuchi, Sachiko Arai, Shigeki Nanjo, Azusa Tanimoto, Akihiro Nishiyama, Katsuhiko Naoki, Seiji Yano
Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer. Cancer science 112 (9) (2021)
Shinji Takeuchi, Tetsunari Hase, Shinobu Shimizu, Masahiko Ando, Akito Hata, Haruyasu Murakami, Takahiro Kawakami, Katsuhiko Nagase, Kenichi Yoshimura, Tadami Fujiwara, Azusa Tanimoto, Akihiro Nishiyama, Sachiko Arai, Koji Fukuda, Nobuyuki Katakami, Toshiaki Takahashi, Yoshinori Hasegawa, Tun Kiat Ko, S Tiong Ong, Seiji Yano
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer. Cancer science 111 (2) (2020)

Koji Fukuda.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Koji Fukuda